Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
vGerman pharma and life science company Merck KGaA today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. 8 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing gedatolisib, a pan-PI3K/mTORC1/2 inhibitor targeting the PAM pathway across multiple solid tumor indications, with pivotal Phase III data now in hand.
Latest News & Features of interest to Merck KGaA
Biotechnology
Mentari Therapeutics has appointed Greg Divis as chief executive officer (CEO) and a member of its board, as the US biotech company prepares to move its migraine prevention pipeline toward the clinic. 20 July 2026
Pharmaceutical
Halozyme Therapeutics today announced that it has entered into a global collaboration and license agreement with Incyte. 20 July 2026
Biotechnology
US biotech Talawar Therapeutics today announced the appointment of Steve Migausky as chief legal and administrative officer. 20 July 2026
Pharmaceutical
US pharma major Bristol Myers Squibb is expanding its partnership with NVIDIA, with plans to deploy an NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems to support AI-led drug discovery and development. 20 July 2026
Pharmaceutical
This article has been developed and funded by Daiichi Sankyo Europe.
With more than 125 years of drug research and development in Japan, Daiichi Sankyo was an early pioneer in antibody-drug conjugates (ADCs), years before the field attracted major industry investment. Along the way, the company has experienced both landmark successes and instructive setbacks – lessons that are now shaping its approach to R&D. 20 July 2026
Biotechnology
South Korea’s Samsung Biologics today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group, a Swiss global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Biotechnology
China’s Kelun-Biotech reported that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with Merck & Co’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda (pembrolizumab) has met its primary endpoint of progression free survival (PFS) at a prespecified interim analysis. 17 July 2026
Latest In Brief for Merck KGaA
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze